Skip to main content
RAPS Convergence 2023 Main banner
Icon Legend
This session is not in your schedule.
This session is in your schedule. Click again to remove it.
Presentation Icons
Requires Pre-Registration or Sign-up
Requires Pre-Registration or Sign-up
Additional Registration Fee
Additional Registration Fee
Invitation Only
Invitation Only
Student Program
Student Program
Networking Opportunity
Networking Opportunity
RAPS Focus Area
RAPS Focus Area
Back

Mary Nwokedi, PharmD

Director of Diversity in Clinical Trials
PhRMA

Mary Nwokedi is a pharmacist by training and is currently the Director of Diversity in Clinical Trials at PhRMA the US industry association representing the country’s leading innovative biopharmaceutical research companies devoted to discovering and developing medicines that enable patients to live longer healthier, and more productive lives. In this role, she has worked on Clinical Trial Diversity initiatives that aims to bridge the gap between patients and novel drug development programs. She currently works with 30+ pharmaceutical member companies and other healthcare ecosystem stakeholders on global clinical trial initiatives to enhance diverse participation.

Mary started off her career in molecular cardiovascular research at Temple School of Medicine and has publications in Nature and the Journal of Molecular and Cellular Cardiology.

Mary holds a Doctor of Pharmacy degree from Howard University (Washington D.C.). She studied Health Policy abroad in Pretoria, South Africa, and worked with the Southern African Development Committee (SADC) to compile a report on the regulatory gap capacity issues that exacerbate inadequate access to medicine to patients in the 13 southern African member nations. She also took a short-term study assignment in UK to study payer models and the impact of policies that impact market access.

Post pharmacy school, Mary accepted a post-doctoral fellowship at Eli Lilly in Global Regulatory Policy and Strategy. She worked on US and International Policy initiatives and collaborated closely with the corporate affairs team on Eli Lilly’s efforts to cooperate with the SDG (sustainable development goals) set by the United Nation.

Mary also worked in Global Oncology Labeling at Merck on the largest oncology therapeutic drug program. She led an effort to standardize label updates in middle/low-income nations for efficient approval and improved access. She also has a Bachelor of Science degree in Biology from Allegheny College (Meadville, PA).

Disclosure information not submitted.

Presentation(s):